



Sequella, Inc.
9610 Medical Center Drive
Rockville, MD 20850
Tele: 301-762-7776
www.sequella.com

MEDIA ADVISORY

January 8, 2007

DR. CAROL NACY, SEQUELLA FOUNDER AND CEO, TO BE GUEST SPEAKER AT WOMEN IN BIO ENTREPRENEUR AND EXECUTIVE FORUM

WHO: Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat diseases of epidemic potential, announced that its CEO, Dr. Carol Nacy, will be a featured panel speaker at the Women in Bio Entrepreneur and Executive Forum entitled "From Seed Investment to M&A: Learn How to Choose the Right Financing for Your Company." Before founding Sequella, Dr. Nacy was Chief Scientific Officer at Anergene, Inc., which was merged with Corixa Corporation in 1998, and Executive Vice President and Chief Scientific Officer of Entremed from 1993 through its successful public offering in June of 1996.

WHAT: The Women in Bio Entrepreneur and Executive Forum will focus on various aspects of choosing and obtaining financing to fund biotechnology companies, and is open to biotechnology industry executives and entrepreneurs. Advanced registration and a fee apply. Other panel speakers include: Cheri Walker, PhD VP of Mergers & Acquisitions of North America, Qiagen and Bill Snider, Partner, Emerging Technology Partners. Women in Bio is a national membership organization of professionals committed to fostering and encouraging entrepreneurship and career development of women active in the life science community. (www.womeninbio.org)

WHEN: Tuesday January 16, 2007 from 6:00 to 9:00 pm

WHERE: KPL Laboratories, 910 Clopper Road, Gaithersburg MD 20898

WHY: Dr. Nacy has raised more than \$26 M from high net worth individuals and peer-reviewed scientific grants in the last nine years to fund the development of products at Sequella. She has built and helped finance 3 biotechnology companies in the last 15 years, experiencing financing ranging from individual investors to M&A to IPO. Prior to her business experience, she was a Science Manager at the Walter Reed Army Institute of Research in Washington, DC. She is on the board of several companies and non-profits, including ASM Resources, Social and Scientific Systems, Women in Bio, and the Sequella Foundation. In September 2006, Dr. Nacy received the National Urban Technology Center Leadership Award in Healthcare for her corporate and scientific interest in developing new tools to combat tuberculosis around the globe and reduce the mortality rate among at-risk populations.

ABOUT SEQUELLA, Inc.

Sequella is a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, infectious disease expertise and diverse product portfolio to proactively address emerging health threats with significant market opportunity. The Company's lead drug candidate SQ109, a new orally-active diamine antibiotic for the treatment of tuberculosis (TB) and other infectious diseases, is presently in Phase I clinical studies. The company's lead diagnostic product candidate, the TB Patch, is completing a large international clinical trial in anticipation of world-wide product registration. For more information, please visit www.sequella.com.

MEDIA CONTACT: Alicia Moran Phone: 703-739-2424 x110.